A61K 39/39558
Against tumor tissues, cells, antigens
Official title: {against tumor tissues, cells, antigens}
A61K39/39558 (Against tumor tissues, cells, antigens) appears on 3,058 US grants and 6,160 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,058
- Published applications
- 6,160
- Assignees
- 1,805
- Inventors
- 8,580
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 3 | 0 |
| 2001 | 6 | 4 |
| 2002 | 5 | 25 |
| 2003 | 4 | 27 |
| 2004 | 6 | 43 |
| 2005 | 4 | 53 |
| 2006 | 12 | 64 |
| 2007 | 12 | 84 |
| 2008 | 24 | 95 |
| 2009 | 34 | 131 |
| 2010 | 42 | 140 |
| 2011 | 64 | 207 |
| 2012 | 71 | 182 |
| 2013 | 136 | 314 |
| 2014 | 155 | 392 |
| 2015 | 198 | 341 |
| 2016 | 202 | 403 |
| 2017 | 228 | 470 |
| 2018 | 201 | 474 |
| 2019 | 258 | 421 |
| 2020 | 272 | 405 |
| 2021 | 272 | 381 |
| 2022 | 198 | 396 |
| 2023 | 196 | 308 |
| 2024 | 193 | 303 |
| 2025 | 164 | 301 |
| 2026 | 91 | 196 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Immunomodulatory and oncolytic minicells and methods of use22 Sep 2026US 12,741,010 B2Vaxiion Therapeutics, Inc.
- Modified antibodies15 Sep 2026US 12,734,208 B2Janux Therapeutics, Inc.
- Anti-VLA-4 antibodies15 Sep 2026US 12,734,236 B2Biogen MA Inc.
- Sarcoma cancer vaccines and uses thereof8 Oct 2026US 2026/0306600 A1
- Combination therapy of tetracyclic quinolone analogs for treating cancer1 Oct 2026US 2026/0294930 A1Senhwa Biosciences, Inc.
- Method for Treating Liver Cancer Using Cell-Immune Agent Composition Delivered via Hepatic Artery1 Oct 2026US 2026/0294965 A1National Defense Medical University
- Use of Amivantamab to Treat Head and Neck Cancer1 Oct 2026US 2026/0295041 A1Janssen Biotech, Inc.
- Anti-cmet antibody1 Oct 2026US 2026/0297202 A1Pierre Fabre Medicament
Most cited
By later US patents
- Antigen-adjuvant compositions and methods1,024US 8,790,658 B2Sanofi Pasteur Limited · 2014
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Immunotherapy of B-cell malignancies using anti-CD22 antibodies395US 6,306,393 B1Immunomedics, Inc. · 2001
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014